News

MGCD265 targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases, which appear to play key roles in tumor development and survival, blood vessel formation (angiogenesis)

Interwest Partners led the financing and existing investors PureTech Ventures participated. The funding is expected to take the company through a clinical proof of concept study. Rox Anderson,

The sale coincides with the closing of the amended merger agreement with Advanced Bionics announced on August 9, 2007. As part of a new schedule of consolidated, fixed

The partnership will own and operate Southwest Kidney Institute’s (SKI) existing dialysis centers and programs designed to provide patients with access to all available treatment modalities. Tom Usilton,

Clinical studies were performed at three evaluation sites in the US using the company’s next generation eSensor XT-8 instrument. These followed the highly successful pre-clinical studies completed in

Upstream’s library of novel compounds has demonstrated encouraging potential in vitro against the tropical parasitic diseases leishmaniasis and trypanosomiasis, and may also have therapeutic utility against the parasite

Preliminary results from this ongoing trial indicate that MB07811 is safe and well tolerated at the doses studied, and based on these findings, the company plans to explore

The company said that, with Seasonale (levonorgestrel and ethinyl estradiol 0.15mg/0.03mg tablets), Canadian women now have a new contraceptive option that will allow them to have just four

According to the companies, if approved for marketing in the US, the trade name for prasugrel will be Effient. Eli Lilly said that the new drug application (NDA)